A new market report on the global systemic sclerosis (scleroderma) market has been added to the repository of MarketResearchReports.biz. The research study, titled “OpportunityAnalyzer: Systemic Sclerosis (Scleroderma) - Opportunity Analysis And Forecast To 2024,” offers a comprehensive and unbiased overview of this market, emphasizing on the opportunities this market is likely to witness during the forecast period.
This 278-page research report provides a detailed evaluation of the worldwide market for scleroderma, taking various industry parameters such as the market chain structure, the dynamics of demand and supply, latest trends, driving forces, challenges, opportunities, and the future prospects in consideration.
Systemic sclerosis (scleroderma) is a complicated autoimmune disease that affects multiple organs in a human, particularly the skin. Although the exact reason behind its occurrence is yet to be identified, it is commonly believed to be instigated by environmental triggers in genetically susceptible individuals.
The clinical presentation of this disease varies from patient-to-patient and its treatment is mostly directed at dealing with its complexities related to infected organ, owing to the lack of systemic treatment options for this disease.
Regionally, the study segments the global systemic sclerosis market into Europe, the U.S., and Japan. Lung fibrosis, skin fibrosis, and digital vasculopathy such as digital ulcers (DUs) and Raynaud’s phenomenon (RP) have been identified as the common types of systemic sclerosis in this research report.
Mycophenolate Mofetil, Methotrexate, Cyclophosphamide, Glucocorticoids, and Azathioprine are the major tissue fibrosis products utilized to treat systemic sclerosis. Besides, Tracleer (bosentan), calcium channel blockers, phosphodiesterase 5 inhibitors, Prostacyclin, angiotensin receptor blockers, and selective serotonin reuptake inhibitors are the key vasculopathy products available in this market, notes the study.
According to the report, three targeted drugs, including Botox by Allergan for digital vasculopathy and two biologic agents for fibrosis, namely Actemra by Genentech/Roches and Orencia by Bristol-Myers Squibb, are expected to be launched during the forecast period. The biologics segment is likely to account for almost 50% of the global systemic sclerosis market by the end of the forecast period. Experts estimate Actemra to emerge as the market leader in the coming years.
The report further anticipates the lack of anti-fibrotic drugs and disease-modifying therapies to present lucrative opportunities to the market players. However, the lack of an appropriated reimbursement scenario is projected to create obstacles for patients in receiving proper therapy.
On the other hand, unmet needs in emerging economies are anticipated to increase research and development activities in the field of systemic sclerosis therapeutics, thereby opening new avenues for market participants over the next few years, states the report.
Apart from this, the report also provides significant information about major early stage pipeline therapies including Adempas (riociguat), Disitertide (P144 cream), Resunab (JBT-101), ARG201, Aimspro, Benlysta (belimumab).
To order report Call Toll Free: 866-997-4948 or send an email on email@example.com